NEW YORK – S2 Genomics said on Tuesday that Japan's RIKEN Center for Integrated Medical Sciences will evaluate and further develop single-cell sequencing applications on the S2 Genomics' Singulator tissue prep system under and early-access program.
According to Livermore, California-based S2 Genomics, the Singulator platform combines enzymatic and mechanical disruption to produce suspensions of cells or nuclei for downstream single-cell applications.
S2 Genomics plans to commercially launch the platform later this year as a research-use-only instrument.
"The Singulator automates and standardizes the dissociation of solid tissues and can improve the quality of single-cell and single-nuclei data from a variety of solid tissue types," S2 Genomics CEO and President Stevan Jovanovich said in a statement. "We are excited to work with the RIKEN IMS to evaluate the performance of the system and to develop new applications for the Singulator platform."